Research and Markets: Investigation Report on China's Temozolomide Market, 2010-2019

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/2m7267/investigation) has announced the addition of the "Investigation Report on China's Temozolomide Market, 2010-2019" report to their offering.

Among all anti- tumor drugs, alkylating agent boasts of the longest history of application. Since nitrogen mustard was used to treat malignant lymphoma in 1942, alkylating agent has become the first-line anti-tumor drug due to its cheap price. The major varieties of alkylating agent are temozolomide and oxaliplatin. First developed by Schering-Plough, temozolomide was approved by the FDA to treat glioma in 1999 and entered China in 2000.

Having efficacy in glioma, leukemia, melanoma, lymphoma and solid tumor, temozolomide can easily penetrate through blood-brain barrier and stay stable in an acid environment with a broad antitumor spectrum and low toxicity. And it can be taken orally in patients who have drug resistance to nitrosoureas.

According to relevant statistics, about 60% of primary brain tumors are malignant ones. The incidence of malignant brain tumor in China is 80-100/1 million and the annual number of new cases is over 200,000. Temozolomide has reported a remarkable growth in global sales since its debut.

According to this market survey, the sales value of temozolomide in sample hospitals rose from about CNY 6 million in 2006 to over CNY 300 million in 2014 with CAGR during the period of 2008- 2014 reaching up to 67%. In 2014, the generic drug of temozolomide made by Tasly was approved to enter the market. Currently, temozolomide products available in the Chinese market come from the following four companies: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd, Orion (Finland), Schering- Plough and Beijing SL Pharmaceutical Co., Ltd, among of which the former three dominate the market and Orion (Finland) had the largest market share of about 50.5% for sales value in 2014.

Key Topics Covered:

1 Related Concepts of Temozolomide

2 Market Profile of Temozolomide in China

3 Survey on Temozolomide Sales in China, 2010-2014

4 Survey on Market Share of Major Temozolomide Manufacturers in China, 2010-2014

5 Survey on Dosage Forms of Temozolomide in China, 2010-2014

6 Reference Price of Temozolomide in Chinese Hospitals in 2014

7 Major Manufacturers of Temozolomide in Chinese Market, 2010-2014

8 Market Outlook of Temozolomide in China, 2015-2019

Companies Mentioned

- Beijing SL Pharmaceutical Co., Ltd

- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd

- Orion

- Schering-Plough

For more information visit http://www.researchandmarkets.com/research/2m7267/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals